Log in  First Connection?
  
EnglishJapaneseFrenchSpanishGerman

Oncology ImagingArchives

Prognostic value of tumour volume based on [18F]PSMA-1007 PET/CT in prostate cancer
Oncology Imaging
 1 min.

 Published on 26/06/2026 |  Original article (Full-text)  | Ingvar, Jacob et al. | European Journal of Hybrid Imaging. Volume 10(1).

Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) enables sensitive detection and staging of prostate cancer, yet its relationship with long-term survival remains unclear. This study aimed to assess whether total lesion volume (TLV) measured on [F]PSMA-1007...

HTML version PDF version  Print abstract

Integrating PET/CT into breast cancer care: a review of recent developments
Oncology Imaging
 1 min.

 Published on 19/06/2026 |  Original article (Full-text)  | Serin Moghrabi et al. | Expert Review of Anticancer Therapy 2025; 25(7): 771-86

Breast cancer (BC) is the most common malignancy in women, classified by histopathological type, grade, receptor status, and stage. PET/CT, particularly with F-FDG, plays a vital role in staging, detecting metastases, and assessing treatment response. This review explores the role of PET/CT in BC management...

HTML version PDF version  Print abstract

Differentiated thyroid cancer and positron emission computed tomography: when, how and why?
Oncology Imaging
 1 min.

 Published on 12/06/2026 |  Original article (Full-text)  | Andrés Coca Pelaz et al. | Expert Review of Anticancer Therapy 2025; 25(10): 1153-64

Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) has become an indispensable tool in oncology, offering both metabolic and anatomical insights into tumor behavior. Most differentiated thyroid carcinomas (DTC) are indolent and therefore FDG PET/CT is not routinely incorporated...

HTML version PDF version  Print abstract

Validation of the PSMA PRIMARY Scoring System and Comparison to an E-PSMA Likert System for [68Ga]Ga-PSMA-11 PET/CT Interpretation in Men With Suspected Radiorecurrent Prostate Cancer.
Oncology Imaging
 1 min.

 Published on 05/06/2026 |  Original article (Full-text)  | Light, Alexander MRCS, et al. | Clinical Nuclear Medicine. Volume 51(1).

To validate the recently published 5-point PRIMARY scoring system against a 5-point European Association of Nuclear Medicine (E-PSMA) Likert system for the detection of intraprostatic recurrence for patients undergoing [68Ga]Ga-PSMA-11 PET/CT who have previously received radiotherapy for prostate cancer...

HTML version PDF version  Print abstract